News | November 14, 2025
LANXESS set to showcase cutting-edge infection control solutions
LANXESS will highlight its commitment to combatting antimicrobial resistance by presenting science-based disinfection solutions
LANXESS will highlight its commitment to combatting antimicrobial resistance by presenting science-based disinfection solutions
New funding to advance non-surgical brain interface technology and expand clinical and engineering capabilities globally
Dragon Copilot integrates generative AI, ambient listening, and natural language processing (NLP) to capture and document care directly
The results demonstrated meaningful reductions in the severity of involuntary movements and notable improvements in patient-reported quality of life
Organic capex during the quarter amounted to Rs. 491.1 crore, supporting ongoing business expansion initiatives
The FDA setback highlights ongoing tensions between patient needs, regulatory processes, and the use of real-world evidence in evaluating treatments for rare diseases
While the trial fell short of demonstrating a statistically significant PFS benefit compared to chemotherapy, early data suggest a potential overall survival advantage
This approval is based on positive results from two Phase 3, global, double-blind, placebo-controlled trials
Relmada expects to initiate its Phase 3 program in the first half of 2026
The said inspection concluded with Zero Form 483 observation
Subscribe To Our Newsletter & Stay Updated
